Multiple Myeloma

Multiple myeloma—a cancer that forms in a type of blood cell called a plasma cell—is a chronic disease that requires ongoing care and monitoring. Our team of specialists partners with you throughout diagnosis and treatment. We use sophisticated diagnostic and genetic tests, some of which were developed at NYU Langone, to guide treatment planning. We also draw upon recent medical advances to provide you with customized therapy. Our doctors have conducted clinical trials to help establish a number of the medications in use today, including immune therapies and targeted medications.

Clinical Trials and Research Studies

Phase 1/2

A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Learn More

Phase 1

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Learn More